| |
 |
 |
 |
 |
 |
 |
 |
 |
|
| HOME
> For Investors > Introduction |
|
|
|
 |
|
|
 |
 |
|
AnGes MG, Inc. is a biopharmaceutical
company founded December 1999 based on the innovative
discovery by researchers of Osaka University. We specialize
in R&D and practical application of genetic medicine
as represented by genetic medication. At present, we are
engaged in developing two new medicines: the Hepatocyte
Growth Factor (HGF) genetic medicine which improves blood
circulation by regenerating blood vessels, and NF B
decoy which controls various inflammations. As for the
HGF genetic medicine against peripheral arterial disease
(PAD) which inhibits blood circulation in the lower limbs,
Phase II clinical trials are being conducted in the United
States, and preparations for Phase III clinical trials
are underway in Japan. |
|
|
We are also making every effort to develop the HVJ-E vector
(a new delivery technology for medicines) through our subsidiary,
Genomidia Inc. Our company is also engaged in many other projects.
It is our mission to provide patients, especially those suffering
from diseases for which no fundamental therapy has yet been
available to date, with innovative drugs as soon as possible
in order to improve their Quality of Life (QOL).
We are as determined as ever to continue our efforts to satisfy
the expectations of patients and families who await new drugs,
as well as those of shareholders, investors, and society as
a whole. |
|
|
